Compare Abeona Therapeutics Inc (ABEO) vs SiTime Corporation (SITM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs SiTime Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.77 (market cap $373.32M), while SiTime Corporation trades at $610.07 (market cap $17.74B). The key difference: SiTime Corporation is far larger — about 47.5× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, SiTime Corporation nearer its low. Which is the better fit depends on your goals.
| ABEO | SITM | |
|---|---|---|
Market Cap | $373.32M | $17.74B |
Sector | Health | Technology |
52-Week High | $7.23 | $901.60 |
52-Week Low | $4.17 | $190.16 |
Enterprise Value | $228.22M | $16.95B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
SITM trades at $615.46, up 2.29% today, showing strong momentum with three consecutive quarterly earnings beats. The stock faces technical headwinds with a bearish moving average signal, while fundamentals reveal robust revenue growth but negative profitability metrics. Recent news highlights the completed acquisition of Renesas' timing business and strong AI-driven demand, with management raising full-year growth guidance to at least 80%.
The outlook remains promising due to accelerating AI infrastructure demand and strategic acquisitions, though investors face risks from negative profit margins and high valuation multiples. Analyst consensus is unanimously bullish with a $743.75 price target representing 21% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
